# The McGill RAAS-COVID-19 Trial

> **NCT04508985** · NA · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 46 (actual)

## Conditions studied

- COVID-19
- Cardiovascular Diseases

## Interventions

- **OTHER:** Temporarily holding the RAAS inhibitor [intervention]
- **OTHER:** RAAS inhibitor [continued standard of care]

## Key facts

- **NCT ID:** NCT04508985
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-17
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04508985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04508985, "The McGill RAAS-COVID-19 Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04508985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*